Intravenous infusion of a replication-selective adenovirus (ONYX-015) in cancer patients: Safety, feasibility and biological activity

Gene Therapy

Volumn 8, Issue 10, 2001, Pages 746-759

  Nemunaitis, J ^a,b   Cunningham, C ^a,b   Buchanan, A ^a   Blackburn, A ^a   Edelman, G ^a   Maples, P ^a   Netto, G ^b   Tong, A ^b   Randlev, B ^c   Olson, S ^d   Kirn, D ^e  

^a Developmental Therapeutics Committee and Co Chair of the Genitourinary Committee   (United States)

^b BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^c ONYX PHARMACEUTICALS   (United States)

^d PFIZER INC   (United States)

^e IMPERIAL COLLEGE SCHOOL OF MEDICINE   (United Kingdom)

Author keywords

Adenovirus; ONYX 015; Replication

Indexed keywords

ANTINEOPLASTIC AGENT; BLEOMYCIN; CARBOPLATIN; CARMUSTINE; CISPLATIN; DACARBAZINE; DOCETAXEL; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; FOLINIC ACID; GAMMA INTERFERON; GEMCITABINE; IFOSFAMIDE; INTERLEUKIN 10; INTERLEUKIN 6; IODINE 131; IRINOTECAN; MITOTANE; NEUTRALIZING ANTIBODY; ONYX 015; PACLITAXEL; PEMETREXED; TAZAROTENE; TEMOZOLOMIDE; THALIDOMIDE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VINCRISTINE;

ADENOVIRUS; ADULT; ADVANCED CANCER; ADVERSE DRUG REACTION; AGED; ANTIBODY TITER; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER PATIENT; CANCER THERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG ACTIVITY; DRUG SAFETY; FEASIBILITY STUDY; FEMALE; FEVER; GENE DELETION; GENETIC ENGINEERING; HUMAN; INFUSION; INTRATUMORAL DRUG ADMINISTRATION; LUNG METASTASIS; MALE; PARTICLE SIZE; PRIORITY JOURNAL; RIGOR; SOLID TUMOR; TOXICITY; VIRUS REPLICATION;

ADENOCARCINOMA; ADENOCARCINOMA, MUCINOUS; ADENOVIRIDAE; ADRENAL GLAND NEOPLASMS; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA; CARCINOMA, PAPILLARY; CARCINOMA, SQUAMOUS CELL; COLONIC NEOPLASMS; FEASIBILITY STUDIES; FEMALE; GENE THERAPY; GENETIC VECTORS; HEAD AND NECK NEOPLASMS; HUMANS; INFUSIONS, INTRAVENOUS; LUNG NEOPLASMS; MALE; MIDDLE AGED; OSTEOSARCOMA; PACLITAXEL; THYROID NEOPLASMS;

ADENOVIRIDAE; ONYX;

EID: 0034990761     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3301424     Document Type: Article

References (91)

1. Adenovirus-mediated correction of the genetic defect in hepatocytes from patients with familial hypercholesterolemia
2. Gene therapy for cancer: What have we done and where are we going?
3. Experimental therapy of human glioma by means of a genetically engineered virus mutant
4. Replication-selective micro-organisms: Fighting cancer with targeted germ warfare
5. Replication-selective adenovirus for cancer
6. Replicating adenoviral gene therapy
7. A novel three-pronged approach to kill cancer cells selectively: Concomitant viral, double suicide gene, and radiotherapy
8. Gene therapy on trial
9. Human papilloma virus E6 proteins bind p53 in vivo and abrogate p53-mediated repression of transcription
10. p53 and DNA polymerase alpha compete for binding to SV40 T antigen
11. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells
12. Clinical implications of the p53 tumor-suppressor gene
13. ONXY-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents
14. The early region 1B 55-kilodalton oncoprotein of adenovirus relieved growth restrictions imposed on viral replication by the cell cycle
15. The replicative capacities of large E1B-null group A and group C adenoviruses are independent of host cell p53 status
16. Replication of ONYX-015, a potential anticancer adenovirus, is independent of p53 status in tumor cells
17. Induction of chemosensitivity in human lung cancer cells in vivo by adenovirus-mediated transfer of the wild-type p53 gene
18. Intravenous administration of ONYX-015, a replication-selective adenovirus, induces antitumoral efficacy
19. ONYX-015 works synergistically with chemotherapy in lung cancer cell lines and primary cultures freshly made from lung cancer patients
20. A controlled trial of intratumoral ONYX-015, a selectively replicating adenovirus, in combination with cisplatin and 5-FU in patients with recurrent head and neck cancer
21. A phase I trial of recombinant human IL-6 in patients with myelodysplastic syndromes and thrombocytopenia
22. Human marrow stromal cells: Response to IL-6 and control of IL-6 expression
23. Toxicological comparison of E2A-deleted and first generation adenoviral vectors expressing alpha-1-antitrypsin after systemic delivery
24. Upregulation of class I major histocompatibility complex antigens by γ-IFN is necessary for T-cell mediated elimination of recombinant adenovirus-injected hepatocytes in vivo
25. Cellular and humoral immune responses to viral antigens create barriers to lung-directed gene therapy with recombinant adenovirus
26. Transient immune blockade prevents formation of neutralizing antibody to recombinant adenovirus and allows repeated gene transfer to mouse liver
27. A phase I study of ONYX-015, an E1B attenuated adenovirus, administered intratumorally to patients with recurrent head and neck cancer
28. Innate immune mechanisms dominate elimination of adenoviral vectors following in vivo administration
29. Circumventing the immune response to adenovirus-mediated gene therapy
30. The route of administration is a major determinant of the transduction efficiency of rat tissues by adenoviral recombinants
31. Enhancement of in vivo adenovirus-mediated gene transfer and expression by prior depletion of tissue macrophages in the target organ
32. Macrophage depletion in the rat after intraperitoneal administration of liposome-encapsulated clodronate: Depletion kinetics and accelerated repopulation of peritoneal and omental macrophages by administration of Freund's adjuvant
33. Kupffer cell function in host defense
34. Macrophages in T-cell line-mediated demyelination and chronic relapsing experimental autoimmune encephalomyelitis in Lewis rats
35. Mechanism of follicular trapping localization of immune complexes and cell remnants after elimination and repopulation of different spleen cell populations
36. Selective depletion of liver and splenic macrophages using lyposomes encapsulating the drug dichloromethylene diphosphonate: Effects of antimicrobial resistance
37. Elimination of mouse splenic macrophages correlates with increased susceptibility to experimental disseminated candidiasis
38. Effects of liposome-encapsulated dichloromethylene diphosphonate on macrophage function and endotoxin-induced mortality
39. The liposome-mediated macrophage 'suicide' technique
40. Macrophage subset repopulation in the spleen differential kinetics after liposome-mediated elimination
41. Depletion and repopulation of macrophages in spleen and liver of rat after intravenous treatment with liposome-encapsulated dichloromethylene diphosphone
42. Liposome mediated depletion of macrophages: Mechanism of action preparation of lyposomes and application
43. Kupffer cell depletion by liposome-delivered drugs: Comparative activity of intracellular clodronate propamidine and ethylenediaminetetraacetic acid
44. Kupffer cell elimination enhances development of liver schizonts of Plasmodium berghei in rats
45. Adenovirus endocytosis requires actin cytoskeleton reorganization mediated by Rho family GTPases
46. 5 promote adenovirus internalization but not virus attachment
47. Early events in the interaction of adenoviruses with HeLa cells. I. Penetration of type 5 and intracellular release of the DNA genome
48. Ultrastructural and immunofluorescence studies of early events in adenovirus-HeLa cell interaction
49. v integrins requires phosphoinositide-3-OH-kinase
50. Rac GTPase interacts specifically with phosphatidylinositol 3-kinase
51. Phosphotidylinositol-3-OH kinase as a direct target of ras
52. Rho family GTPases bind to phosphoinositide kinase
53. Activation of phosphoinositide 3-kinase activity by Cdc42Hs binding to p85
54. Assessment of recombinant adenoviral vectors for hepatic gene therapy
55. Role of adenovirus antigens in the induction of virus neutralizing antibody
56. Neutralization of adenoviruses: Kinetics, stoichiometry and mechanisms
57. Stepwise dismantling of adenovirus 2 during entry into cells
58. Vitronectin receptor antibodies inhibit infection of HeLa and A549 cells by adenovirus type 12 but not by adenovirus type 2
59. 5 integrin is necessary for efficient adenovirus-mediated gene transfer in the human airway
60. Interaction between HeLa cells and adenovirus type 2 virions neutralized by different antisera
61. Adenoviridae: The viruses and their replication
62. MHC class I-restricted cytotoxic T-lymphocytes to viral antigens destroy hepatocytes in mice-infected with E1-deleted recombinant adenoviruses
63. Strain related variations in adenovirally mediated transgene expression from mouse hepatocytes in vivo: Comparisons between immunocompetent and immunodeficient inbred strains
64. Cellular and humoral immune response to adenoviral vectors containing factor IX gene: Tolerization of factor IX and vector antigens allows for long-term expression
65. Persistence of replication-deficient adenovirus-mediated gene transfer in lung of immune-deficient (nu/nu) mice
66. The impact of development stage, route of administration and the immune system on adenovirus-mediated gene transfer
67. Long-term hepatic adenovirus-mediated gene expression in mice following CTLA41g administration
68. Administration of an adenovirus containing the human CFTR cDNA to the respiratory tract of individuals with cystic fibrosis
69. Recombinant IL-12 prevents formation of blocking IfA antibodies to recombinant adenovirus and allows repeated gene therapy to mouse lung
70. Use of transient CD4 lymphocyte depletion to prolong transgene expression of E1-deleted adenoviral vectors
71. Anti-T-cell receptor monoclonal antibody prolongs transgene expression following adenovirus-mediated in vivo gene transfer to mouse synovium
72. Suppression of the immune response to an adenovirus vector and enhancement of intratumoral transgene expression by low dose etoposide
73. Gene therapy for hemophilia B: Host immunosuppression prolongs the therapeutic effect of adenovirus-mediated factor IX expression
74. Cytotoxic T-lymphocyte target proteins and their major histocompatibility complex class I restriction in response to adenovirus vectors delivered to mouse liver
75. Ablation of E2A in recombinant adenoviruses improves transgene persistence and decreases inflammatory response in mouse liver
76. FK506 immunosuppression to control the immune reactions triggered by first-generation adenovirus-mediated gene transfer
77. Immunosuppression by FK506 markedly prolongs expression of adenovirus-delivered transgene in skeletal muscles of adult dystrophic (mdx) mice
78. Adenovirus proteins that subvent host defenses
79. The constitutive expression of the immunomodulatory gp 19k protein in E1-, E3 adenoviral vectors strongly reduces the host cytotoxic T-cell response against the vector
80. E3 transcription unit of adenovirus
81. An efficient and flexible system for construction of adenovirus vectors with insertions or deletions in early regions. 1 and 3
82. Insertion of the adenoviral E3 region into a recombinant viral vector prevents antiviral humoral and cellular immune responses and permits long-term gene expression
83. Model system for studying the effects of adenovirus E3 gene on virulence in vivo
84. Mouse anti-adenovirus cytotoxic T-lymphocytes. Inhibition of lysis by E3 gp19K but not E1 14.7K
85. Region E3 of adenovirus: A cassette of genes involved in host immunosurveillance and virus-cell interactions
86. Novel proteins associated with MHC class I antigens in cells expressing the adenovirus protein E3/19K
87. Association of human class I MHC alleles with the adenovirus E8/19K protein
88. Characterization of factors involved in modulating persistence of transgene expression from recombinant adenovirus in the mouse lung
89. Adenovirus-mediated cytotoxicity of chronic lymphocytic leukemia cells
90. Prostate attenuated replication competent adenovirus (ARCA) CN706: A selective cytotoxic for prostate-specific antigen-positive prostate cancer cells
91. Adenovirus proteins from both E1B reading frames are required for transformation of rodent cells by viral injection and DNA transfection